Profilin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox-protein
| protein_name = Profilin-1
| gene = PFN1
| uniprot_id = P07737
| pdb_ids = 1PFL, 2BT0, 3J45
| molecular_weight = ~15000 Da
| subcellular_localization = Cytoplasm, Cytoskeleton
| protein_family = Profilin family
}}
Profilin-1 is a small actin-binding protein encoded by the PFN1 gene. Profilin-1 is essential for regulating actin polymerization, cytoskeletal dynamics, and cellular motility. Mutations in PFN1 cause familial amyotrophic lateral sclerosis (ALS), establishing cytoskeletal dysfunction as a key pathway in motor neuron disease.
| Feature | Details |
|---|---|
| Size | 140 amino acids |
| Structure | All-beta fold (seven-stranded β-sheet) |
| Actin-binding | Surface binding, not major conformational changes |
| Polyproline binding | Recognition motif for proline-rich sequences |
| Homodimer | Forms homodimers in solution |
| Site | Binding Partner | Function |
|---|---|---|
| Actin-binding | G-actin | Monomer sequestration, polymerization |
| Polyproline | Formin, VASP, WASP | Cytoskeletal regulation |
| Phospholipid | PIP2 | Membrane association |
Profilin-1 is a central regulator of actin polymerization:
| Function | Mechanism |
|---|---|
| Cell migration | Lamellipodia, filopodia formation |
| Cytokinesis | Contractile ring formation |
| Neuronal morphogenesis | Growth cone dynamics |
| Synaptic plasticity | Dendritic spine changes |
| Axonal guidance | Growth cone steering |
| Aspect | Details |
|---|---|
| Inheritance | Autosomal dominant |
| Prevalence | ~1-2% of familial ALS |
| Mutations | C71G, M114T, G118V, E117D |
| Mechanism | Gain of toxic function |
Pathogenic Mechanisms:
Disrupted actin dynamics:
Mitochondrial dysfunction:
Autophagy impairment:
RNA granule defects:
| Disease | Relationship |
|---|---|
| Frontotemporal Dementia | PFN1 mutations in some cases |
| Parkinson's Disease | Alpha-synuclein toxicity |
| Cancer metastasis | Profilin-1 upregulation |
| Strategy | Status | Description |
|---|---|---|
| Gene therapy | Preclinical | AAV-PFN1 delivery |
| Actin modulators | Research | Targeting cytoskeletal dynamics |
| Autophagy enhancers | Research | mTOR inhibitors |
| Mitochondrial protectants | Research | CoQ10, antioxidants |
Wu CH, et al. (2012). "Profilin 1 mutations cause familial ALS." Nature 488(7412):499-503. PMID:22760635
Smith BN, et al. (2013). "Exome analysis in familial ALS." Neurology 81(17):1514-1521. PMID:24078620
Fil D, et al. (2017). "Pathological features of PFN1-ALS." Acta Neuropathol Commun 5(1):26. PMID:28399893
Yang C, et al. (2016). "PFN1 and mitochondrial dysfunction." Neurobiol Aging 46:140-148. PMID:27524571
Boci M, et al. (2021). "PFN1 and ALS." Brain 144(3):e26. PMID:33783514
Zhang Z, et al. (2020). "PFN1 deficiency and cytoskeletal defects." Cell Rep 33(1):108193. PMID:33096033
Aladesuyi A, et al. (2023). "Profilin-1 in ALS." Nat Rev Neurol 19(5):289-302. PMID:36964512
Deng J, et al. (2022). "Actin-binding compounds for ALS." J Med Chem 65(8):6213-6228. PMID:35476218
The study of Profilin 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.